Search Medical Condition
Please enter condition
Please choose location

Hennebont, France Clinical Trials

A listing of Hennebont, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (22) clinical trials

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

The study duration for an individual patient will start from the signature of the informed consent, will include a period to assess eligibility (screening period) of up to approximately 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days following the last administration of study drug, ...

Phase

1.39 miles

Learn More »

Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy

The sponsor is developing a new paediatric formulation of vigabatrin to better adjust the dose to body weight and to limit waste of unused drug. The currently marketed vigabatrin (Sabril™) form only exists as 500 mg film coated tablets (for adults and children above 6 years) and 500 mg granules ...

Phase N/A

1.39 miles

Learn More »

Plegridy Observational Program

The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice. ...

Phase N/A

1.39 miles

Learn More »

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.

Phase

1.39 miles

Learn More »

Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome

The Overlap Syndrome is defined by the coexistence of chronic obstructive pulmonary disease (COPD) and an apnea - hypopnea syndrome obstructive sleep (SAHS). The interaction between these two diseases is responsible for deepest nocturnal desaturation, decreased sensitivity to CO2, more pronounced sleep alterations, more frequent daytime hypercapnia, a higher risk ...

Phase N/A

1.39 miles

Learn More »

Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

ROSCO-CF is a phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa. The aim of this study is to assess ...

Phase

1.39 miles

Learn More »

Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

This study assesses the long‐term effectiveness of adalimumab in subjects starting a treatment for ulcerative colitis in real life conditions, namely to describe the time to loss of clinical benefit in a time to event approach.

Phase N/A

1.39 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

1.39 miles

Learn More »

A Phase III of ADT +/- Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-na ve Prostate Cancer.

Eligible patients can be randomize in the trial after his consent form has been signed, and after all inclusion and non-inclusion criteria have been checked. The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone), arm C(ADT + radiotherapy) or arm D (ADT + ...

Phase

1.39 miles

Learn More »

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients. Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately 15% of patients with AML. The outcome of first line chemotherapy treatment is poor and many patients fail to attain complete remission ...

Phase

1.39 miles

Learn More »